Medical/Pharmaceuticals
Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive
ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of es...
Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease
HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today that it has signed a global, exclusive license agreemen...
SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021
Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma...
Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
HOUSTON and SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkels...
Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced a$75 million Series A finan...
VISTA Eye Specialist Shares How It Thrives during the COVID-19 Pandemic
PETALING JAYA, Malaysia, Nov. 29, 2021 /PRNewswire/ -- As part of VISTA Eye Specialists' (VISTA) core value of 'Giving Back to the Community', VISTA does not only give for charity, but believes strongly in sharing of knowledge and experiences. Other than sharing via conferences and publications, ...
Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research
TAIPEI, Nov. 27, 2021 /PRNewswire/ -- Following the inspiring opening speech, "Future Perspective of Cancer Immunotherapy," delivered by Nobel Prize and Tang Prize laureate Prof.Tasuku Honjo at the 14th Asia Pacific Federation of Pharmacologist Conference (APFP) onNovember 26, the 2020 Tang Prize...
ASUS and Medical Professionals Showcase Five Smart Healthcare Achievements
SINGAPORE, Nov. 26, 2021 /PRNewswire/ -- ASUS Intelligent Cloud Services (AICS) today introduced five smart medical solutions during its AICS Medical Open House. The xHIS platform, the Lumos EMR search platform, the Drug Safety Service, the Miraico smart medical coding assistant and the Personal ...
Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100%
of evaluable patients with Stage IV prostate cancer have had efficacy
responses, utilising one or more standard measures of disease.
DEP® cabazitaxel
Róbert Wessman-led Aztiq and Innobic join forces in $475m acquisition of Lotus Pharmaceutical and Adalvo to create a global pharmaceutical powerhouse
REYKJAVÍK, Iceland, Nov. 26, 2021 /PRNewswire/ -- Aztiq
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100% of evaluable patients with (Stage IV) metastatic prostat...
Premium Red Ginseng Brand CheongKwanJang to Celebrate 122nd anniversary
SEOUL, South Korea, Nov. 26, 2021 /PRNewswire/ -- Korea Ginseng Corp (KGC)
celebrates the 122nd anniversary of its premium red ginseng brand,
CheongKwanJang.
Premium Red Ginseng Brand CheongKwanJang to Celebrate 122nd anniversary
SEOUL, South Korea, Nov. 26, 2021 /PRNewswire/ -- Korea Ginseng Corp (KGC)
celebrates the 122nd anniversary of its premium red ginseng brand,
CheongKwanJang.
Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks
SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
- New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, andAsia-based global healthcare investors Tybourne Capital Management and NSG Ventures - Following the most recent strategic investment of $26 million from Guardant Heal...
How CIIE offers a window for multinational companies into the Chinese market
SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Opening up is the hallmark of contemporaryChina. The China International Import Expo (CIIE) is poised to shape a link betweenChina and the global market. Scheduled from Nov 5 to 10, the 4th CIIE presented a total of 422 new products, technologies, and s...
Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia
SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with locally advanced or metastatic solid tumours has been approved by the ...
More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with...
Elekta: Interim report, May-October 2021/22
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- The increasing need for investments in cancer care and radiotherapy across the globe supported a gradual market recovery during the quarter. Our orders grew with double digits, and despite the continued global supply chain challenges we secured good revenu...
Innovative €250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi
BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire/ -- Fresenius Kabi was delighted to announce the winner of their innovative JUMPstart education program and research grant onSeptember 10, 2021. JUMPstart is an initiative that aims to nurture research in the field of parenteral nutrition through th...
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 287 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 280 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 276 media titles]
2026-10-15 12:59New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21